Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone

References

• Ahmad, F., Rossen, L., & Sutton, P. (2020). Provisional drug overdose death counts. CDC National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
   Google Scholar
• Alegría, M., Page, J. B., Hansen, H., Cauce, A. M., Robles, R., Blanco, C., Cortes, D. E., Amaro, H., Morales, A., & Berry, P. (2006). Improving drug treatment services for Hispanics: Research gaps and scientific opportunities. Drug and Alcohol Dependence, 84(Suppl 1), S76–S84. https://doi.org/10.1016/j.drugalcdep.2006.05.009
   PubMedGoogle Scholar
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425596
   Google Scholar
• Bailey, G. L., Herman, D. S., & Stein, M. D. (2013). Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification. Journal of Substance Abuse Treatment, 45(3), 302–305. https://doi.org/10.1016/j.jsat.2013.04.002
   PubMed Web of Science ®Google Scholar
• Binswanger, I. A., Blatchford, P. J., Mueller, S. R., & Stern, M. F. (2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. https://doi.org/10.7326/0003-4819-159-9-201311050-00005
   PubMed Web of Science ®Google Scholar
• Carey, K. B. (1997). Reliability and validity of the time-line follow-back interview among psychiatric outpatients: A preliminary report. Psychology of Addictive Behaviors, 11(1), 26–33. https://doi.org/10.1037/0893-164X.11.1.26
   Web of Science ®Google Scholar
• Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., Dackis, C., & O’Brien, C. P. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry, 63(2), 210. https://doi.org/10.1001/archpsyc.63.2.210
   PubMed Web of Science ®Google Scholar
• Darke, S., Marel, C., Slade, T., Ross, J., Mills, K. L., & Teesson, M. (2015). Patterns and correlates of sustained heroin abstinence: Findings from the 11-year follow-up of the Australian treatment outcome study. Journal of Studies on Alcohol and Drugs, 76(6), 909–915. https://doi.org/10.15288/jsad.2015.76.909
   PubMed Web of Science ®Google Scholar
• Darke, S., Ross, J., Mills, K. L., Williamson, A., Havard, A., & Teesson, M. (2007). Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addictive Behaviors, 32(9), 1897–1906. https://doi.org/10.1016/j.addbeh.2007.01.014
   PubMed Web of Science ®Google Scholar
• Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P. (2004). Depressive symptoms during buprenorphine vs. methadone maintenance: Findings from a randomised, controlled trial in opioid dependence. European Psychiatry: The Journal of the Association of European Psychiatrists, 19(8), 510–513. https://doi.org/10.1016/j.eurpsy.2004.09.002
   PubMed Web of Science ®Google Scholar
• Dennis, M. L., Foss, M. A., & Scott, C. K. (2007). An eight-year perspective on the relationship between the duration of abstinence and other aspects of recovery. Evaluation Review, 31(6), 585–612. https://doi.org/10.1177/0193841X07307771
   PubMed Web of Science ®Google Scholar
• Dreifuss, J. A., Griffin, M. L., Frost, K., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., Selzer, J., Hatch-Maillette, M., Sonne, S. C., & Weiss, R. D. (2013). Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence, 131(1–2), 112–118. https://doi.org/10.1016/j.drugalcdep.2012.12.010
   PubMed Web of Science ®Google Scholar
• Fals-Stewart, W., O’Farrell, T. J., Freitas, T. T., McFarlin, S. K., & Rutigliano, P. (2000). The timeline followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology, 68(1), 134–144. https://doi.org/10.1037//0022-006X.68.1.134
   PubMed Web of Science ®Google Scholar
• Flynn, P. M., Joe, G. W., Broome, K. M., Simpson, D. D., & Brown, B. S. (2003). Recovery from opioid addiction in DATOS. Journal of Substance Abuse Treatment, 25(3), 177–186. https://doi.org/10.1016/S0740-5472(03)00125-9
   PubMed Web of Science ®Google Scholar
• Goehl, L., Nunes, E., Quitkin, F., & Hilton, I. (1993). Social networks and methadone treatment outcome: The costs and benefits of social ties. The American Journal of Drug and Alcohol Abuse, 19(3), 251–262. https://doi.org/10.3109/00952999309001617
   PubMed Web of Science ®Google Scholar
• Greiner, M. G., Shulman, M., Choo, T.-H., Scodes, J., Pavlicova, M., Campbell, A. N. C., Novo, P., Fishman, M., Lee, J. D., Rotrosen, J., & Nunes, E. V. (2021). Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. Journal of Substance Abuse Treatment, 131, 108447. https://doi.org/10.1016/j.jsat.2021.108447
   PubMed Web of Science ®Google Scholar
• Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23(1), 56–62. https://doi.org/10.1136/jnnp.23.1.56
   PubMed Web of Science ®Google Scholar
• Hasin, D., Liu, X., Nunes, E., McCloud, S., Samet, S., & Endicott, J. (2002). Effects of major depression on remission and relapse of substance dependence. Archives of General Psychiatry, 59(4), 375–380. https://doi.org/10.1001/archpsyc.59.4.375
   PubMed Web of Science ®Google Scholar
• Hser, Y.-I. (2007). Predicting long-term stable recovery from heroin addiction: Findings from a 33-year follow-up study. Journal of Addictive Diseases, 26(1), 51–60. https://doi.org/10.1300/J069v26n01_07
   PubMed Web of Science ®Google Scholar
• Hser, Y.-I., Evans, E., Huang, D., Weiss, R., Saxon, A., Carroll, K. M., Woody, G., Liu, D., Wakim, P., Matthews, A. G., Hatch-Maillette, M., Jelstrom, E., Wiest, K., McLaughlin, P., & Ling, W. (2016). Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction (Abingdon, England), 111(4), 695–705. https://doi.org/10.1111/add.13238
   PubMed Web of Science ®Google Scholar
• Hser, Y. I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001). A 33-year follow-up of narcotics addicts. Archives of General Psychiatry, 58(5), 503–508. https://doi.org/10.1001/archpsyc.58.5.503
   PubMed Web of Science ®Google Scholar
• Joe, G. W., Simpson, D. D., & Broome, K. M. (1999). Retention and patient engagement models for different treatment modalities in DATOS. Drug and Alcohol Dependence, 57(2), 113–125. https://doi.org/10.1016/S0376-8716(99)00088-5
   PubMed Web of Science ®Google Scholar
• Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet (London, England), 377(9776), 1506–1513. https://doi.org/10.1016/S0140-6736(11)60358-9
   PubMed Web of Science ®Google Scholar
• Krupitsky, E., Zvartau, E., Blokhina, E., Verbitskaya, E., Wahlgren, V., Tsoy-Podosenin, M., Bushara, N., Burakov, A., Masalov, D., Romanova, T., Tyurina, A., Palatkin, V., Yaroslavtseva, T., Pecoraro, A., & Woody, G. (2016). Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. The American Journal of Drug and Alcohol Abuse, 42(5), 614–620. https://doi.org/10.1080/00952990.2016.1197231
   PubMed Web of Science ®Google Scholar
• Latif, Z.-H., Šaltyte Benth, J., Solli, K. K., Opheim, A., Kunoe, N., Krajci, P., Sharma-Haase, K., & Tanum, L. (2019). Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: A randomized clinical trial and follow-up study. JAMA Psychiatry, 76(2), 127–134. https://doi.org/10.1001/jamapsychiatry.2018.3537
   PubMed Web of Science ®Google Scholar
• Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, J., Peavy, K. M., Ross, S., Salazar, D., Schkolnik, P., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. Lancet (London, England), 391(10118), 309–318. https://doi.org/10.1016/S0140-6736(17)32812-X
   PubMed Web of Science ®Google Scholar
• Marsch, L. A., Stephens, M. A. C., Mudric, T., Strain, E. C., Bigelow, G. E., & Johnson, R. E. (2005). Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence. Experimental and Clinical Psychopharmacology, 13(4), 293–302. https://doi.org/10.1037/1064-1297.13.4.293
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2003). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews, 2, CD002209. https://doi.org/10.1002/14651858.CD002209
   PubMedGoogle Scholar
• Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2004). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, 3, CD002207. https://doi.org/10.1002/14651858.CD002207.pub2
   Google Scholar
• McKenna, R. M. (2017). Treatment use, sources of payment, and financial barriers to treatment among individuals with opioid use disorder following the national implementation of the ACA. Drug and Alcohol Dependence, 179, 87–92. https://doi.org/10.1016/j.drugalcdep.2017.06.028
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992). The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment, 9(3), 199–213. https://doi.org/10.1016/0740-5472(92)90062-S
   PubMed Web of Science ®Google Scholar
• Mitchell, M. M., Schwartz, R. P., Choo, T.-H., Pavlicova, M., O’Grady, K. E., Gryczynski, J., Stitzer, M. L., Nunes, E. V., & Rotrosen, J. (2021). An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Drug and Alcohol Dependence, 219, 108422. https://doi.org/10.1016/j.drugalcdep.2020.108422
   PubMed Web of Science ®Google Scholar
• Mysels, D. J., Cheng, W. Y., Nunes, E. V., & Sullivan, M. A. (2011). The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. The American Journal of Drug and Alcohol Abuse, 37(1), 22–26. https://doi.org/10.3109/00952990.2010.540281
   PubMed Web of Science ®Google Scholar
• Naji, L., Dennis, B. B., Bawor, M., Plater, C., Pare, G., Worster, A., Varenbut, M., Daiter, J., Marsh, D. C., Desai, D., Thabane, L., & Samaan, Z. (2016). A prospective study to investigate predictors of relapse among patients with opioid use disorder treated with methadone. Substance Abuse: Research and Treatment, 10, SART.S37030. https://doi.org/10.4137/SART.S37030
   Google Scholar
• Najt, P., Fusar-Poli, P., & Brambilla, P. (2011). Co-occurring mental and substance abuse disorders: A review on the potential predictors and clinical outcomes. Psychiatry Research, 186(2–3), 159–164. https://doi.org/10.1016/j.psychres.2010.07.042
   PubMed Web of Science ®Google Scholar
• Nosyk, B., Anglin, M. D., Brecht, M.-L., Lima, V. D., & Hser, Y.-I. (2013). Characterizing durations of heroin abstinence in the California Civil Addict Program: Results from a 33-year observational cohort study. American Journal of Epidemiology, 177(7), 675–682. https://doi.org/10.1093/aje/kws284
   PubMed Web of Science ®Google Scholar
• Nunes, E. V., Bisaga, A., Krupitsky, E., Nangia, N., Silverman, B. L., Akerman, S. C., & Sullivan, M. A. (2020). Opioid use and dropout from extended-release naltrexone in a controlled trial: Implications for mechanism. Addiction (Abingdon, England), 115(2), 239–246. https://doi.org/10.1111/add.14735
   PubMed Web of Science ®Google Scholar
• Nunes, E. V., Lee, J. D., Sisti, D., Segal, A., Caplan, A., Fishman, M., Bailey, G., Brigham, G., Novo, P., Farkas, S., & Rotrosen, J. (2016). Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. Contemporary Clinical Trials, 51, 34–43. https://doi.org/10.1016/j.cct.2016.09.006
   PubMed Web of Science ®Google Scholar
• Nunes, E. V., Pavlicova, M., Hu, M.-C., Campbell, A., Miele, G., Hien, D., & Klein, D. F. (2011). Baseline matters: The importance of covariation for baseline severity in the analysis of clinical trials. The American Journal of Drug and Alcohol Abuse, 37(5), 446–452. https://doi.org/10.3109/00952990.2011.596980
   PubMed Web of Science ®Google Scholar
• Nunes, E. V., Sullivan, M. A., & Levin, F. R. (2004). Treatment of depression in patients with opiate dependence. Biological Psychiatry, 56(10), 793–802. https://doi.org/10.1016/j.biopsych.2004.06.037
   PubMed Web of Science ®Google Scholar
• Peciña, M., Karp, J. F., Mathew, S., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J.-K. (2019). Endogenous opioid system dysregulation in depression: Implications for new therapeutic approaches. Molecular Psychiatry, 24(4), 576–587. https://doi.org/10.1038/s41380-018-0117-2
   PubMed Web of Science ®Google Scholar
• Peckham, A. D., Griffin, M. L., McHugh, R. K., & Weiss, R. D. (2020). Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder. Drug and Alcohol Dependence, 213, 108122. https://doi.org/10.1016/j.drugalcdep.2020.108122
   PubMed Web of Science ®Google Scholar
• Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33(5), 337–343. https://doi.org/10.3109/07853890109002087
   PubMed Web of Science ®Google Scholar
• Romero‐Gonzalez, M., Shahanaghi, A., DiGirolamo, G. J., & Gonzalez, G. (2017). Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders. The American Journal on Addictions, 26(8), 838–844. https://doi.org/10.1111/ajad.12641
   PubMed Web of Science ®Google Scholar
• Rounsaville, B. J., Kosten, T. R., Weissman, M. M., & Kleber, H. D. (1986). Prognostic significance of psychopathology in treated opiate addicts: A 2.5-year follow-up study. Archives of General Psychiatry, 43(8), 739–745. https://doi.org/10.1001/archpsyc.1986.01800080025004
   PubMed Web of Science ®Google Scholar
• Saxena, P. P., & Bodkin, J. A. (2019). Opioidergic agents as antidepressants: Rationale and promise. CNS Drugs, 33(1), 9–16. https://doi.org/10.1007/s40263-018-0584-7
   PubMed Web of Science ®Google Scholar
• Scott, C. K., Dennis, M. L., Laudet, A., Funk, R. R., & Simeone, R. S. (2011). Surviving drug addiction: the effect of treatment and abstinence on mortality. American Journal of Public Health, 101(4), 737–744. https://doi.org/10.2105/AJPH.2010.197038
   PubMed Web of Science ®Google Scholar
• Sobell, L., & Sobell, M. (2000). Alcohol timeline followback (TLFB). In Handbook of psychiatric measures (pp. 477–479). American Psychiatric Association.
   Google Scholar
• Soyka, M., Strehle, J., Rehm, J., Bühringer, G., & Wittchen, H.-U. (2017). Six-year outcome of opioid maintenance treatment in heroin-dependent patients: Results from a naturalistic study in a nationally representative sample. European Addiction Research, 23(2), 97–105. https://doi.org/10.1159/000468518
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2019). Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001; NSDUH Series H-55, p. 114). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data
   Google Scholar
• Sullivan, M. A., Rothenberg, J. L., Vosburg, S. K., Church, S. H., Feldman, S. J., Epstein, E. M., Kleber, H. D., & Nunes, E. V. (2006). Predictors of retention in naltrexone maintenance for opioid dependence: Analysis of a stage I trial. The American Journal on Addictions, 15(2), 150–159. https://doi.org/10.1080/10550490500528464
   PubMed Web of Science ®Google Scholar
• The Opioid Crisis and the Hispanic/Latino Population: An Urgent Issue. (2020). Substance abuse and mental health services administration. Office of Behavioral Health Equity.
   Google Scholar
• Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-assisted treatment for opiate dependence: A systematic review. Journal of Addictive Diseases, 35(1), 22–35. https://doi.org/10.1080/10550887.2016.1100960
   PubMed Web of Science ®Google Scholar
• Volkow, N. D. (2020). Collision of the COVID-19 and addiction epidemics. Annals of Internal Medicine, 173(1), 61–62. https://doi.org/10.7326/M20-1212
   PubMed Web of Science ®Google Scholar
• Weiss, R. D., Griffin, M. L., Marcovitz, D. E., Hilton, B. T., Fitzmaurice, G. M., McHugh, R. K., & Carroll, K. M. (2019). Correlates of opioid abstinence in a 42-month post-treatment naturalistic follow-up study of prescription opioid dependence. The Journal of Clinical Psychiatry, 80(2):18m12292. https://doi.org/10.4088/JCP.18m12292
   Google Scholar
• Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., Gardin, J., Griffin, M. L., Gourevitch, M. N., Haller, D. L., Hasson, A. L., Huang, Z., Jacobs, P., Kosinski, A. S., Lindblad, R., McCance-Katz, E. F., Provost, S. E., Selzer, J., Somoza, E. C., … Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Archives of General Psychiatry, 68(12), 1238–1246. https://doi.org/10.1001/archgenpsychiatry.2011.121
   PubMed Web of Science ®Google Scholar
• Weiss, R. D., Potter, J. S., Griffin, M. L., Provost, S. E., Fitzmaurice, G. M., McDermott, K. A., Srisarajivakul, E. N., Dodd, D. R., Dreifuss, J. A., McHugh, R. K., & Carroll, K. M. (2015). Long-term outcomes from the national drug abuse treatment clinical trials network prescription opioid addiction treatment study. Drug and Alcohol Dependence, 150, 112–119. https://doi.org/10.1016/j.drugalcdep.2015.02.030
   PubMed Web of Science ®Google Scholar
• Wells, K., Klap, R., Koike, A., & Sherbourne, C. (2001). Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. The American Journal of Psychiatry, 158(12), 2027–2032. https://doi.org/10.1176/appi.ajp.158.12.2027
   PubMed Web of Science ®Google Scholar
• Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019). Development of a cascade of care for responding to the opioid epidemic. The American Journal of Drug and Alcohol Abuse, 45(1), 1–10. https://doi.org/10.1080/00952990.2018.1546862
   PubMed Web of Science ®Google Scholar
• Williams, A. R., Samples, H., Crystal, S., & Olfson, M. (2020). Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. The American Journal of Psychiatry, 177(2), 117–124. https://doi.org/10.1176/appi.ajp.2019.19060612
   PubMed Web of Science ®Google Scholar
• Zhu, Y., Evans, E., Mooney, L. J., Saxon, A., Kelleghan, A., Yoo, C., & Hser, Y.-I. (2018). Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine/naloxone in a multi-site trial. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology, 13(4), 488–497. https://doi.org/10.1007/s11481-018-9801-x
   PubMed Web of Science ®Google Scholar